Is IRD or URGN more profitable?

Urogen Pharma has a net margin of -94.83% compared to Opus Genetics' net margin of -892.36%. Urogen Pharma's return on equity of 0.00% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Opus Genetics -892.36% -338.88% -191.21% Urogen Pharma -94.83% N/A -62.85%

Which has stronger earnings & valuation, IRD or COAG?

Hemab Therapeutics has lower revenue, but higher earnings than Opus Genetics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Opus Genetics $14.20M 23.72 -$49.59M -$1.33 N/A Hemab Therapeutics N/A N/A N/A N/A N/A

Which has better valuation & earnings, IRD or HROW?

Harrow has higher revenue and earnings than Opus Genetics. Harrow is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Opus Genetics $14.20M 23.72 -$49.59M -$1.33 N/A Harrow $272.30M 4.58 -$5.14M -$0.41 N/A

Is IRD or HROW more profitable?

Harrow has a net margin of -5.57% compared to Opus Genetics' net margin of -892.36%. Harrow's return on equity of 19.59% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Opus Genetics -892.36% -338.88% -191.21% Harrow -5.57% 19.59% 2.26%

Opus Genetics (IRD) Competitors

$4.08 +0.05 (+1.24%)

Closing price 04:00 PM Eastern

Extended Trading

$4.03 -0.05 (-1.32%)

As of 07:57 PM Eastern

Compare

IRD vs. URGN, MLTX, COAG, HROW, and MPLT

Should you buy Opus Genetics stock or one of its competitors? MarketBeat compares Opus Genetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Opus Genetics include Urogen Pharma (URGN), MoonLake Immunotherapeutics (MLTX), Hemab Therapeutics (COAG), Harrow (HROW), and Maplight Therapeutics (MPLT). These companies are all part of the "pharmaceutical products" industry.

How does Opus Genetics compare to Urogen Pharma?

Opus Genetics (NASDAQ:IRD) and Urogen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Comparatively, 4.7% of Urogen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Urogen Pharma has a net margin of -94.83% compared to Opus Genetics' net margin of -892.36%. Urogen Pharma's return on equity of 0.00% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-892.36%	-338.88%	-191.21%
Urogen Pharma	-94.83%	N/A	-62.85%

Opus Genetics has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market.

Opus Genetics currently has a consensus target price of $10.67, indicating a potential upside of 161.44%. Urogen Pharma has a consensus target price of $36.67, indicating a potential upside of 30.12%. Given Opus Genetics' stronger consensus rating and higher possible upside, analysts clearly believe Opus Genetics is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.81
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Urogen Pharma had 4 more articles in the media than Opus Genetics. MarketBeat recorded 6 mentions for Urogen Pharma and 2 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 0.96 beat Urogen Pharma's score of 0.10 indicating that Opus Genetics is being referred to more favorably in the media.

Company	Overall Sentiment
Opus Genetics	Positive
Urogen Pharma	Neutral

Opus Genetics has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	23.72	-$49.59M	-$1.33	N/A
Urogen Pharma	$109.79M	12.51	-$153.49M	-$2.75	N/A

Summary

Opus Genetics beats Urogen Pharma on 9 of the 16 factors compared between the two stocks.

How does Opus Genetics compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

MoonLake Immunotherapeutics currently has a consensus target price of $23.85, suggesting a potential upside of 33.97%. Opus Genetics has a consensus target price of $10.67, suggesting a potential upside of 161.44%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Opus Genetics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.81

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. MoonLake Immunotherapeutics' return on equity of -85.15% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
Opus Genetics	-892.36%	-338.88%	-191.21%

MoonLake Immunotherapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 12.1% of MoonLake Immunotherapeutics shares are owned by company insiders. Comparatively, 11.7% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Opus Genetics has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
Opus Genetics	$14.20M	23.72	-$49.59M	-$1.33	N/A

In the previous week, MoonLake Immunotherapeutics had 5 more articles in the media than Opus Genetics. MarketBeat recorded 7 mentions for MoonLake Immunotherapeutics and 2 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 0.96 beat MoonLake Immunotherapeutics' score of 0.43 indicating that Opus Genetics is being referred to more favorably in the news media.

Company	Overall Sentiment
MoonLake Immunotherapeutics	Neutral
Opus Genetics	Positive

Summary

Opus Genetics beats MoonLake Immunotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Opus Genetics compare to Hemab Therapeutics?

Opus Genetics (NASDAQ:IRD) and Hemab Therapeutics (NASDAQ:COAG) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Hemab Therapeutics has lower revenue, but higher earnings than Opus Genetics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	23.72	-$49.59M	-$1.33	N/A
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A

In the previous week, Hemab Therapeutics had 2 more articles in the media than Opus Genetics. MarketBeat recorded 4 mentions for Hemab Therapeutics and 2 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 0.96 beat Hemab Therapeutics' score of 0.00 indicating that Opus Genetics is being referred to more favorably in the media.

Company	Overall Sentiment
Opus Genetics	Positive
Hemab Therapeutics	Neutral

15.0% of Opus Genetics shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Opus Genetics presently has a consensus price target of $10.67, indicating a potential upside of 161.44%. Hemab Therapeutics has a consensus price target of $41.75, indicating a potential upside of 54.63%. Given Opus Genetics' stronger consensus rating and higher possible upside, analysts clearly believe Opus Genetics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.81
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Hemab Therapeutics has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Hemab Therapeutics' return on equity of 0.00% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-892.36%	-338.88%	-191.21%
Hemab Therapeutics	N/A	N/A	N/A

Summary

Opus Genetics beats Hemab Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Opus Genetics compare to Harrow?

Opus Genetics (NASDAQ:IRD) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Harrow has higher revenue and earnings than Opus Genetics. Harrow is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	23.72	-$49.59M	-$1.33	N/A
Harrow	$272.30M	4.58	-$5.14M	-$0.41	N/A

Opus Genetics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Harrow has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market.

Opus Genetics presently has a consensus price target of $10.67, suggesting a potential upside of 161.44%. Harrow has a consensus price target of $69.43, suggesting a potential upside of 107.50%. Given Opus Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Opus Genetics is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.81
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Harrow had 2 more articles in the media than Opus Genetics. MarketBeat recorded 4 mentions for Harrow and 2 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 0.96 beat Harrow's score of 0.52 indicating that Opus Genetics is being referred to more favorably in the media.

Company	Overall Sentiment
Opus Genetics	Positive
Harrow	Positive

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Comparatively, 12.8% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Harrow has a net margin of -5.57% compared to Opus Genetics' net margin of -892.36%. Harrow's return on equity of 19.59% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-892.36%	-338.88%	-191.21%
Harrow	-5.57%	19.59%	2.26%

Summary

Harrow beats Opus Genetics on 9 of the 17 factors compared between the two stocks.

How does Opus Genetics compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Opus Genetics (NASDAQ:IRD) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

15.0% of Opus Genetics shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by company insiders. Comparatively, 11.7% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Opus Genetics had 1 more articles in the media than Maplight Therapeutics. MarketBeat recorded 2 mentions for Opus Genetics and 1 mentions for Maplight Therapeutics. Opus Genetics' average media sentiment score of 0.96 beat Maplight Therapeutics' score of 0.00 indicating that Opus Genetics is being referred to more favorably in the news media.

Company	Overall Sentiment
Maplight Therapeutics	Neutral
Opus Genetics	Positive

Maplight Therapeutics presently has a consensus price target of $37.78, suggesting a potential upside of 29.07%. Opus Genetics has a consensus price target of $10.67, suggesting a potential upside of 161.44%. Given Opus Genetics' higher probable upside, analysts clearly believe Opus Genetics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.00
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.81

Opus Genetics has higher revenue and earnings than Maplight Therapeutics. Opus Genetics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Opus Genetics	$14.20M	23.72	-$49.59M	-$1.33	N/A

Maplight Therapeutics has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Maplight Therapeutics' return on equity of 0.00% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Opus Genetics	-892.36%	-338.88%	-191.21%

Summary

Opus Genetics beats Maplight Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Opus Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRD vs. The Competition

Export

Metric	Opus Genetics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$332.74M	$3.30B	$6.64B	$12.06B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-3.07	18.68	24.75	23.76
Price / Sales	23.72	297.55	508.64	105.22
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	18.55	8.06	10.47	6.72
Net Income	-$49.59M	$23.83M	$3.56B	$337.35M
7 Day Performance	2.26%	-2.82%	-1.11%	-2.54%
1 Month Performance	-18.24%	2.22%	1.28%	1.42%
1 Year Performance	288.57%	37.70%	21.20%	24.71%

Opus Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRD Opus Genetics	3.2816 of 5 stars	$4.08 +1.2%	$10.67 +161.4%	+287.5%	$332.74M	$14.20M	N/A	14
URGN Urogen Pharma	2.8382 of 5 stars	$26.54 -1.8%	$36.67 +38.2%	+269.7%	$1.32B	$109.79M	N/A	200	Insider Trade Gap Up
MLTX MoonLake Immunotherapeutics	3.1087 of 5 stars	$17.87 -5.0%	$23.85 +33.4%	-61.6%	$1.32B	N/A	N/A	2	Positive News Analyst Forecast
COAG Hemab Therapeutics	4.1303 of 5 stars	$27.47 +1.3%	$41.75 +52.0%	N/A	$1.28B	N/A	N/A	72	Quiet Period Expiration
HROW Harrow	4.5097 of 5 stars	$32.86 -3.7%	$69.43 +111.3%	+11.9%	$1.27B	$272.30M	N/A	180	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRD) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Opus Genetics (IRD) Competitors

IRD vs. URGN, MLTX, COAG, HROW, and MPLT

How does Opus Genetics compare to Urogen Pharma?

Summary

How does Opus Genetics compare to MoonLake Immunotherapeutics?

Summary

How does Opus Genetics compare to Hemab Therapeutics?

Summary

How does Opus Genetics compare to Harrow?

Summary

How does Opus Genetics compare to Maplight Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRD vs. The Competition

Opus Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Opus Genetics (IRD) Competitors

IRD vs. URGN, MLTX, COAG, HROW, and MPLT

How does Opus Genetics compare to Urogen Pharma?

Do insiders & institutionals believe in IRD or URGN?

Is IRD or URGN more profitable?

Which has more volatility & risk, IRD or URGN?

Do analysts recommend IRD or URGN?

Does the media favor IRD or URGN?

Which has stronger valuation & earnings, IRD or URGN?

Summary

How does Opus Genetics compare to MoonLake Immunotherapeutics?

Do analysts recommend MLTX or IRD?

Is MLTX or IRD more profitable?

Which has more risk and volatility, MLTX or IRD?

Do institutionals and insiders have more ownership in MLTX or IRD?

Which has preferable valuation and earnings, MLTX or IRD?

Does the media prefer MLTX or IRD?

Summary

How does Opus Genetics compare to Hemab Therapeutics?

Which has stronger earnings & valuation, IRD or COAG?

Does the media favor IRD or COAG?

Do insiders and institutionals hold more shares of IRD or COAG?

Do analysts prefer IRD or COAG?

Is IRD or COAG more profitable?

Summary

How does Opus Genetics compare to Harrow?

Which has better valuation & earnings, IRD or HROW?

Which has more volatility & risk, IRD or HROW?

Do analysts recommend IRD or HROW?

Does the media prefer IRD or HROW?

Do insiders & institutionals have more ownership in IRD or HROW?

Is IRD or HROW more profitable?

Summary

How does Opus Genetics compare to Maplight Therapeutics?

Do institutionals and insiders have more ownership in MPLT or IRD?

Does the media refer more to MPLT or IRD?

Do analysts recommend MPLT or IRD?

Which has stronger valuation and earnings, MPLT or IRD?

Is MPLT or IRD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRD vs. The Competition

Opus Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools